| Ytd | -66.35% | |
| 1y | -70.89% |
| Open | 1.37 | Prev Close | 1.38 | Low | 1.36 | High | 1.44 | Mkt Cap | 2.68M |
| Vol | 8.81K | Avg Vol | 91.87K | EPS | -10.60 | P/E | -0.13 | Forward P/E | -0.43 |
| Beta | 1.70 | Short Ratio | 0.42 | Inst. Own | 3.24% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-14 | 50-d Avg | 1.59 | 200-d Avg | 3.36 | 1yr Est | 13.83 |
DWTX News
Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biotechnology
ATLANTA, July 20, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”)
HC Wainwright & Co. analyst Sean Lee reiterates Dogwood Therapeutics (NASDAQ:DWTX) with a Buy
Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a biopharmace
Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(0.15) per share which met the anal
HC Wainwright & Co. analyst Sean Lee reiterates Dogwood Therapeutics (NASDAQ:DWTX) with a Buy
Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a company tha
Dogwood licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin Pharma
Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(0.26) per share which beat the ana